Clinical Trials Logo

Clinical Trial Summary

This study will examine the safety and effectiveness of a new surgical procedure to correct congenital nystagmus-a disorder of eye muscle-vision-brain coordination characterized by rapid to and fro eye movements (oscillation). Nystagmus usually begins in infancy or early childhood; its effect on vision varies greatly among patients. Current treatments, such as prism glasses, acupuncture, electronic nerve stimulation, contact lenses, various drug treatments, and others have had limited success.

Patients with congenital nystagmus sometimes have other eye problems as well, such as cataracts, glaucoma, astigmatism or strabismus (cross-eyes). When these patients have eye muscle surgery to correct a problem, such as strabismus, their nystagmus also improves. Researchers think that simply cutting the muscles might produce this beneficial effect. This study will test this hypothesis-the horizontal muscles of the eye will be cut and then reattached in the same position. This procedure has been tried in one sheepdog with good results.

This small preliminary trial will include five adult patients with congenital nystagmus who have no other treatment options. It will evaluate the safety of the surgery and its effect on eye oscillation and vision. If the procedure is found to be safe, additional patients will be studied.

Patients will have a medical history, basic physical examination, complete eye examination, and electro-oculography (eye movement recordings) to determine if eligibility for the study. Those accepted into the study will undergo eye muscle surgery and followup eye examinations and electro-oculography at 1 week, 6 weeks, 6 months, 1 year, 2 years and 3 years after surgery.


Clinical Trial Description

This is a prospective open-label pilot study of a new surgical approach never before performed on humans. Subjects of this study are patients with congenital nystagmus and no other treatment options. Using standard surgical techniques we will determine if simple tenotomy with reattachment will reduce their nystagmus. An oculographic reduction of the nystagmus is measured by the Nystagmus Acuity Function (NAF), considered a primary outcome. Phase II of the study includes binocular visual acuity as a second primary outcome. A 20% improvement in NAF will be considered a clinically significant reduction in nystagmus and a 10 letter or greater improvement in binocular vision will be considered a clinically significant improvement in visual acuity. Secondary oculographic outcomes include breadth or creation of null zones, slow phase velocity during foveation, and nystagmus intensity. Other secondary outcomes will include visual functions, assessed pre- and post-operatively using standard measures of binocular visual acuity (Phase I) and the National Eye Institute-Visual Function Questionnaire (NEI-VFQ) in patients 18 years or older. Extraocular muscle proprioception and afferent innervation in control of ocular motor behavior will also be examined as secondary outcomes. The study will initially be limited to 5 adults 18 years of age and older (Phase I). However, recognizing that there are many visual differences between younger and older patients, the study will then be expanded to include children after the initial pilot study (Phase II). The NEI DSMC, ICRRC, and IRB will assess adverse events after Phase I, and if in their judgment there are no serious safety concerns surrounding the procedure, Phase II will be initiated. The initiation of Phase II begins with enrollment of 5 adults and after review of 1 week post-surgical safety data, 5 patients under the age of 18 will be enrolled. Patients who have a clinical and oculographic diagnosis of congenital nystagmus as determined by a screening exam at NEI and have not had previous extraocular muscle surgery and have no other nystagmus treatment options (a gaze null or convergence damping) are eligible. They must be able to undergo a complete ophthalmic and ocular-motor evaluation and be cooperative for standard eye movement recordings. After informed consent and assent, eligible patients will undergo a complete ophthalmic and ocular motor examination. They will have their eye movements recorded using a standard oculographic recording technique and protocol. In Phase II these recordings will take place three preoperative visits at least 2 weeks apart and no more than 4 months prior to surgery. Using routine operative techniques for extraocular muscle surgery, the patient will have all four horizontal recti tenotomized and reattached at their original insertions. In addition to routine post-operative care, complete ocular examinations and eye movement recordings will be repeated at 1 week, 6 weeks, 6 months, and12 months after surgery. The patient's subjective visual responses (e.g., visual acuity and binocular function) will be compared before and after surgery. Objective changes in the eye movement recordings and binocular visual acuity post-operatively will be quantified and compared to preoperative values. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00001866
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase Phase 2
Start date August 1999
Completion date November 2001

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03603301 - Vision in Children Born to Opioid-dependent Methadone-maintained Mothers
Completed NCT00001861 - Screening for Studies on Nystagmus and Strabismus N/A
Completed NCT00702832 - Effect of Vestibular Rehabilitation - a Randomized Controlled Trial N/A
Completed NCT00928954 - Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus N/A